The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 02, 2014

Filed:

Sep. 30, 2011
Applicants:

Catherine J. Luke, Frederick, MD (US);

Adrian Vilalta, San Diego, CA (US);

Mary K. Wloch, San Diego, CA (US);

Thomas G. Evans, San Diego, CA (US);

Andrew J. Geall, San Marcos, CA (US);

Gretchen S. Jimenez, San Diego, CA (US);

Inventors:

Catherine J. Luke, Frederick, MD (US);

Adrian Vilalta, San Diego, CA (US);

Mary K. Wloch, San Diego, CA (US);

Thomas G. Evans, San Diego, CA (US);

Andrew J. Geall, San Marcos, CA (US);

Gretchen S. Jimenez, San Diego, CA (US);

Assignee:

Vical Incorporated, San Diego, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/145 (2006.01); C12N 15/44 (2006.01); C12N 15/63 (2006.01); A61K 48/00 (2006.01); C12N 7/00 (2006.01); C07K 16/10 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 7/00 (2013.01); C12N 2760/16134 (2013.01); C12N 2760/16151 (2013.01); C07K 16/1018 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55555 (2013.01); C07K 2317/34 (2013.01); A61K 39/145 (2013.01); A61K 39/00 (2013.01); A61K 2039/55511 (2013.01);
Abstract

The present invention is directed to compositions and methods for enhancing the immune response of a human in need of protection against influenza virus (IV) infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof, or a protein encoded thereby. The polynucleotide is incorporated into the cells of the human in vivo, and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo. The IV protein (in purified form or in the form of an inactivated IV vaccine) is also administered in an immunologically effective amount.


Find Patent Forward Citations

Loading…